•  
  •  
  •  
  •  

2026-07-22 01:32:56

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  Injection

Stock Report

  • Lupin receives approval from U.S. FDA for Ranluspec™ (ranibizumab) Injection
  • Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
  • NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290
  • Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
  • Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry
  • Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Lupin Launches Liraglutide Injection in the United States
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
  • Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Pantoprazole Sodium for Injection, 40 mg/vial - Single-Dose Vial
  • Wockhardt files fast-acting Insulin Aspart injection with DCGI
  • Shilpa Medicare Ltd announces USFDA Approval for Bortezomib Injection NDA 212782
  • Alembic Pharmaceuticals announces USFDA Final Approval for Nelarabine Injection, 250 mg/50 mL
  • Caplin Steriles Ltd gets USFDA approval for Ephedrine Sulfate injection USP
  • Alembic Pharmaceuticals announces USFDA Tentative Approval for Selexipag for Injection, 1,800 mcg/vial
  • Alembic Pharmaceuticals announces USFDA Final Approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
  • Sun Pharma and Moebius Medical Ltd present Phase 2b study on MM-II
  • Cairn Oil & Gas commences India's largest commercial ASP injection in Mangala, Rajasthan
  • Gland Pharma receives approval for Edaravone Injection

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025